Summary
Three drugs that have been approved for PV include JAKAFI/JAKAVI (ruxolitinib), BESREMi (ropeginterferon alfa-2B/AOP2014/P1101), and PEGASYS (peginterferon alfa-2a). JAKAFI and BESREMi are approved in the US, Europe, and Japan, while PEGASYS is approved only in Europe.
JAKAFI is nearing its patent expiry in 2028; however, as of now, its revenue is increasing continuously due to stronger-than-expected demand, particularly from patients with polycythemia vera and graft-versus-host disease.
Key players involved in developing potential therapies for the treatment of PV include Protagonist Therapeutics and Takeda (Rusfertide), Italfarmaco (DUVYZAT),...
